S1 guideline for the treatment of suppurative hidradenitis/acne inversa (ICD-10 Section: L73.2);S1-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa * (ICD-10 Ziffer: L73.2)

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue SUPPL. 5, 2012, Pages

  Zouboulis, Christos C ^a   Bechara, Falk G ^b   Fritz, Klaus ^c,k,l   Kurzen, Hjalmar ^d   Liakou, Aikaterini I ^a   Marsch, Wolfgang C ^e   Milling, Annett ^f   Nast, Alexander ^g   Podda, Maurizio ^h   Taube, Klaus M ^e   Wienert, Volker ⁱ   Winkler, Thomas ^j  

^a DESSAU MEDICAL CENTER   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Hautärzte und Laserzentrum Landau und Kandel ^*  (Germany)

^d Niedergelassener Dermatologe   (Germany)

^e MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^f Klinikum Frankfurt Oder GmbH   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h KLINIKUM DARMSTADT   (Germany)

ⁱ Früherer Leitlinie Beauftragter   (Germany)

^j 1 Vorsitzender der Deutschen Interessengemeinschaft Akne Inversa EV   (Germany)

^k UNIVERSITY OF BERN   (Switzerland)

^l UNIVERSITY OF OSNABRÜCK   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACNE; ACNE INVERSA; ARTICLE; ICD-10; PRACTICE GUIDELINE; SUPPURATIVE HIDRADENITIS;

ANTI-BACTERIAL AGENTS; DERMATOLOGIC AGENTS; DERMATOLOGIC SURGICAL PROCEDURES; DERMATOLOGY; GERMANY; HIDRADENITIS SUPPURATIVA; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84865610005     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2012.08006.x     Document Type: Article

References (178)

1. Nast A, Bayerl C, Borelli C, Degitz K, Dirschka T, Erdmann R, Fluhr J, Gieler U, Hartwig R, Meigel E-M, Möller S, Ochsendorf F, Podda M, Rabe T, Rzany B, Schink S, Zouboulis CC, Gollnick H. S2k-Leitlinie zur Therapie der Akne. J Dtsch Dermatol Ges 2010; 8(Suppl 2): S1-S59.
2. Lorenz W, Ollenschläger G, Geraedts M, Gerlach FM, Gandjour A, Helou A, Kirchner H, Koller M, Lauterbach KW, Reinauer H, Sitter H, Thomeczek C. Das Leitlinienmanual von AWMF und ÄZQ. Z Arztl Fortbild Qualitatssich 2001; 95(suppl 1): 1-84.
3. Matusiak U, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010; 90: 264-8.
4. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831-9.
5. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J; Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of cases. J Am Acad Dermatol 2007; 56: 621-3.
6. Jansen T, Altmeyer P, Plewig G. Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol 2001; 15: 532-40.
7. Lee R A, Yoon A, Kist J. Hidradenitis suppurativa: an update. Adv Dermatol 2007; 23: 289-306.
8. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2: 9-16.
9. Meixner D, Schneider S, Krause M, Sterry W. Acne inversa. J Dtsch Dermatol Ges 2008; 6: 189-96.
10. Von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2010; 144: 809-13.
11. Alikhan A, Lynch PJ, Eisen D. Hidradenitis suppurativa: A comprehensive review. J Am Acad Dermatol 2009; 60: 539-61.
12. Esmann S, Jemec GBE. Work, personal relationship and sexuality are influenced most by hidradenitis suppurativa (abstract). Acta Derm Venerol 2009; 89: 577-8.
13. Velpeau A. Aissele. In: Bechet Jeune Z, ed.: Dictionnaire de médecine, un repertoire générale des Sciences Médicals sous le rapport théorique et pratique. 2nd éd, vol. 2. Paris, 1839: 1839-91.
14. Verneuil A. Etudes sur les tumeurs de la peau; de quelques maladies des glandes sudoripares. Arch Gen Med 1854; 4: 447-68, 693-705.
15. Brunsting HA. Hidradenitis suppurativa; abscess of apocrine sweat glands- a study of the clinical and pathologic features with a report of twenty-two cases and a review of the literature. Arch Dermatol Syphilol 1939; 39: 108-20.
16. Pillsbury DM, Shelley WB, Kligman AM. Bacterial infections of the skin. In: Pillsbury DM, ed.: Dermatology. 1st ed. Philadelphia: W. B. Saunders, 1956: 482-4, 489.
17. Plewig G, Kligman AM. Acne: Morphogenesis and Treatment. Springer-Verlag, Berlin, 1975: 192-3.
18. Plewig G, Steger M. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G, eds.: Acne and related disorders. London: Martin Dunitz, 1989: 345-57.
19. Kurzen H, Kurokawa I, Jemec GBE, Emtestam L, Sellheyer K, Giamarellos- Bourboulis EJ, Nagy I, Bechara FG, Sartorius K, Lapins J, Krahl D, Altmeyer P, Revuz J, Zouboulis CC. What causes hidradenitis suppurativa? Exp Dermatol 2008; 17: 455-72.
20. Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366: 158-64.
21. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Roujeau JC, Bonnelye G, Grob JJ, Bastuji- Garin S. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 5: 596-601.
22. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-4.
23. Kurzen H, Schönfelder-Funcke S, Hartschuh W. Surgical treatment of Acne inversa at the University of Heidelberg. Int J Coloproct 2000; 22: 76-80.
24. Sellheyer K, Krahl D. What causes acne inversa (or hidradenitis suppurativa)? - the debate continues. J Cutan Pathol 2008; 35: 701-3.
25. von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19: 533-7.
26. von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/ acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011; 164: 367-71.
27. Jemec GB, Gniadecka M. Sebum excretion in hidradenitis suppurativa. Dermatology 1997; 194: 325-8.
28. Kamp S, Fiehn AM, Stenderup K, Rosada C, Pakkenberg B, Kemp K, Dam TN, Jemec GB. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol 2011; 164: 1017-22.
29. Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999; 140: 90-5.
30. van der Zee HH, Laman JD, de Ruiter L, Dik WA, Prens EP. Adalimumab (anti-TNF-a) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol 2012; 166: 298-305.
31. Wolk K, Warszawska K, Hoeflich C, Witte E, Schneider-Burrus S, Witte K, Kunz S, Buss A, Roewert HJ, Krause M, Lukowsky A, Volk HD, Sterry W, Sabat R. Deficiency of IL-contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011; 186: 1228-39.
32. Schlapbach C, Hönni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65: 790-8.
33. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, Mouktaroudi M, Spyridaki E, Baziaka F, Pelekanou A, Giamarellou H, Stavrianeas NG. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007; 156: 51-6.
34. Hunger RE, Surovy AM, Hassan AS, Braathen LR, Yawalkar N. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br J Dermatol 2008; 158: 691-7.
35. Emelianov VU, Bechara FG, Gläser R, Langan EA, Taungjaruwinai WM, Schröder JM, Meyer KC, Paus R. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 2012; 166(5): 1023-34.
36. Schlapbach C, Yawalkar N, Hunger RE. Human beta-defensin-2 and psoriasin are overexpressed in lesions of acne inversa. J Am Acad Dermatol 2009; 61: 58-65.
37. Von Der Werth JM, Williams HC, Raeburn JA. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol 2000; 142: 947-53.
38. Gao M, Wang PG, Cui Y, Yang S, Zhang YH, Lin D, Zhang KY, Liang YH, Sun LD, Yan KL, Xiao FL, Huang W, Zhang XJ. Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3. J Invest Dermatol 2006; 126: 1302-6.
39. Al-Ali FM, Ratnamala U, Mehta TY, Naveed M, Al-Ali MT, Al-Khaja N, Sheth JJ, Master DC, Maiti AK, Chetan GK, Nath SK, Radhakrishna U. Hidradenitis suppurativa (or Acne inversa) with autosomal dominant inheritance is not linked to chromosome 1p21.1-1q25.3 region. Exp Dermatol 2010; 19: 851-3.
40. Wang B, Yang W, Wen W, Sun J, Su B, Liu B, Ma D, Lv D, Wen Y, Qu T, Chen M, Sun M, Shen Y, Zhang X. Gamma-secretase gene mutations in familial acne inversa. Science 2010; 330: 1065.
41. Nassar D, Hugot JP, Wolkenstein P, Revuz J. Lack of association between CARD15 gene polymorphisms and hidradenitis suppurativa: a pilot study. Dermatology 2007; 215: 359.
42. Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, Chen W, Nagy I, Picardo M, Suh DH, Ganceviciene R, Schagen S, Tsatsou F, Zouboulis CC. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18: 821-32.
43. Von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2010; 144: 809-13.
44. Cesko E, Korber A, Dissemond J. Smoking and obesity are associated factors in acne inversa: results of a retrospective investigation in 100 patients. Eur J Dermatol 2009; 19: 490-3.
45. Feyerabend C, Ings RM, Russel MA. Nicotine pharmacokinetics and its application to intake from smoking. Br J Clin Pharmacol 1985; 19: 239-47.
46. Kintz P, Henrich A, Cirimele V, Ludes B. Nicotine monitoring in sweat with a sweat patch. J Chromatogr B Biomed Sci Appl 1998; 705: 357-61.
47. Balabanova Balabanova S, Krupienski M. Untersuchungen zum Nachweis von Nikotin im ekkrinen Schweiß nach Stimulation der Schweißdrüsen während einer Nikotinkarenz. Hautarzt 1995; 46: 255-8.
48. Hana A, Booken D, Henrich C, Gratchev A, Maas-Szabowski N, Goerdt S, Kurzen H. Functional significance of non-neuronal ACh in skin epithelia. Life Sci 2007; 25: 2214-20.
49. Pavia CS, Pierre A, Nowakowski J.Antimicrobial activity of nicotine against a spectrum of bacterial and fungal pathogens. J Med Microbiol 2000; 49: 675-6.
50. Durmaz R, Tekerekoglu MS, Kalcioglu T, Ozturan O. Nasal carriage of methicillin-resistant Staphylococcus aureus among smokers and cigarette factory workers. New Microbiol 2001; 24: 143-7.
51. Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in culturesfrom the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999; 140: 90-5.
52. Kawashima K, Fujii T. The lymphocytic cholinergic system and its biological function. Life Sci 2003; 72: 2101-9.
53. Kurzen H, Wessler I, Kirkpatrick CJ, Kawashima K, Grando SA. The nonneuronal cholinergic system of human skin. Horm Metab Res 2007; 39: 125-35.
54. Kurzen H, Berger H, Jager C, Hartschuh W, Naher H, Gratchev A, Goerdt S, Deichmann M. Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skin. J Invest Dermatol 2004; 123: 937-49.
55. Sorensen LT, Nielsen HB, Kharazmi A, Gottrup F. Effect of smoking and abstention on oxidative burst and reactivity of neutrophils and monocytes. Surgery 2004; 136: 1047-53.
56. Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Bastuji- Garin S. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51-7.
57. Poli F, Wolkenstein P, Revuz J. Back and face involvement in hidradenitis suppurativa. Dermatology 2010; 221: 137-41.
58. Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000; 26: 638-643.
59. Breuninger H. Therapie des Pilonidalsinus und der Acne inversa. Hautarzt 2004; 55: 254-8.
60. von Laffert M, Stadie V, Ulrich J, Marsch WC, Wohlrab J. Morphology of pilonidal sinus disease: some evidence of its being a unilocalized type of hidradenitis suppurativa. Dermatology 2011; 223: 349-55.
61. Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122: 763-9.
62. Constantinou C, Widom K, Desantis J, Obmann M. Hidradenitis suppurativa complicated by squamous cell carcinoma. Am Surg 2008; 74: 1177-81.
63. Williams ST, Busby RC, De Muth RJ, Nelson H. Perineal hidradenitis suppurativa: presentation of two unusual complications and a review. Ann Plast Surg 1991; 26: 456-62.
64. Van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease are they associated? Results of a pilot study. Br J Dermatol 2010; 162: 195-7.
65. Church JM, Fazio VW, Lavery JC, Oakley JR, Milsom JW. The differential diagnosis and comorbidity of HP and perianal Crohns disease - a further support to this association. Int J Colorectal Dis 1993; 8: 117-9.
66. Jemec GB. The sympathology of hidradenitis suppurativa in women. Br J Dermatol 1988; 119: 345-50.
67. Wortsman X, Jemec GB. Real-time compound imaging ultrasound of hidradenitis suppurativa. Dermatol Surg 2007; 33: 1340-2.
68. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk RK, Roenigk HH Jr, eds: Dermatologic Surgery. Principles and Practice. 2nd edn. New York: Dekker, 1996: 623-45.
69. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23: 985-98.
70. Lam J, Krakowski AC, Friedlander SF. Hidradenitis suppurativa (acne inversa): management of a recalcitrant disease. Pediatr Dermatol 2007; 24: 465-73.
71. Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol 2012; 148(4): 439-46.
72. Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorect Dis 1998; 13: 164-8.
73. Altmann S, Fansa H, Schneider W. Axillary hidradenitis suppurativa: A further option for surgical treatment. J Cutan Med Surg 2004; 8: 6-10.
74. Ellis LZ. Hidradenitis suppurativa: Surgical and other management techniques. Dermatol Surg 2011. [Epub ahead of print].
75. van Rappard DC, Mooij JE, Mekkes JR. Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol 2012; 26(7): 898-902.
76. van Hattem S, Spoo JR, Horväth B, Jonkman MF, Leeman FW. Surgical treatment of sinuses by deroofing in hidradenitis suppurativa. Dermatol Surg 2012; 38: 494-7.
77. van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63: 475-80.
78. Wollina U, Tilp M, Meseg A, Schönlebe J, Heinig B, Nowak A. Management of severe anogenital acne inversa (hidradenitis suppurativa). Dermatol Surg 2011; 38: 110-7.
79. Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000; 26: 638-43.
80. Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J 1987; 294: 487-9.
81. Bohn J, Svensson H. Surgical treatment of hidradenitis suppurativa. Scand J Plast Reconstr Surg Hand Surg 2001; 35: 305-9.
82. Tanaka A, Hatoko M, Tada H, Kuwahara M, Mashiba K, Yurugi S. Experience with surgical treatment of hidradenitis suppurativa. Ann Plast Surg 2001; 47: 636-42.
83. Mandal A, Watson J. Experience with different treatment modules in hidradenitis suppurativa: a study of 106 cases. Surgeon 2005; 3: 23-6.
84. Dalrymple JC, Monaghan JM. Treatment of hidradenitis suppurativa with the carbon dioxide laser. Br J Surg 1987; 74: 420.
85. Sherman AI, Reid R. CO2 laser for suppurative hidradenitis of the vulva. J Reprod Med 1991; 36: 113-7.
86. Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping- secondary intention technique. Br J Dermatol 1994; 131: 551-6.
87. Finley EM, Ratz IL. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol 1996; 34: 465-9.
88. Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol 2002; 47: 280-5.
89. Madan V, Hindle E, Hussain W, August PJ. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol 2008; 159: 1309-14.
90. Krasner BD, Hamzavi FH, Murakawa GJ, Hamzavi IH. Dissecting cellulitis treated with the long-pulsed Nd:YAG laser. Dermatol Surg 2006; 32: 1039-44.
91. Sehgal VN, Verma P, Sawant S, Paul M. Contemporary surgical treatment of hidradenitis suppurativa (HS) with a focus on the use of the diode hair laser in a case. J Cosmet Laser Ther 2011; 13: 180-90.
92. Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium- doped Yttrium Aluminium Garnet Laser. Dermatol Surg 2009; 35: 1188-98.
93. Downs A. Smoothbeam laser treatment may help improve hidradenitis suppurativa but not Hailey-Hailey disease. J Cosmet Laser Ther 2004; 6: 163-4.
94. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin Int J Dermatol 1983; 22: 325-8.
95. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1988; 39: 971-4.
96. Boer J, Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 2010; 35: 36-40.
97. Buimer MG, Ankersmit MF, Wobbes T, Klinkenbijl JH. Surgical treatment of hidradenitis suppurativa with gentamicin sulfate: a prospective randomized study. Dermatol Surg 2008; 34: 224-7.
98. Mendona CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006; 154: 977-8.
99. van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009; 219: 143-7.
100. Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, Pouget F, Viallette C, Wolkenstein P, Bastuji- Garin S. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219: 148-54.
101. McManus P, Iheanacho I. Dont use minocycline as first line oral antibiotic in acne. BMJ 2007; 334: 154.
102. ACOG. The use of hormonal contraception in women with coexisting medical conditions. ACOG Prac Bull 2000; 18: 1-13.
103. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002; 46: 917-23.
104. Arowojolu AO, Gallo MF, Lopez LM, Grims DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2009:CD004425.
105. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol 2002; 119: 992-1007.
106. Kraft JN, Searle GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J. Cutan Med Surg 2007; 11: 125-31.
107. Mortimer PS, Dawber RP, Gales MA, Moore RA. A double blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 1986; 115: 263-8.
108. Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol 1986; 115: 269-74.
109. Joseph MA, Jayaseelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat 2005; 16: 75-8.
110. Farrell AM, Randall VA, Vafaee T, Dawber RP. Finasteride as therapy for hidradenitis suppurativa. Br J Dermatol 1999; 141: 1138-9.
111. Zouboulis CC, Rabe T. Hormonelle Antiandrogene in der Acnetherapie. J Dtsch Dermatol Ges 2010; 8 (Suppl 1): S60-74.
112. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
113. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
114. Vartiainen M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with a combiphasic desogestrel- containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care 2001; 6: 46-53.
115. Gollnick H, Albring M, Brill K. Efficacitè de lacètate de cyprotèrone oral associe à lèthinylestradiol dans le traitement de lacnè tardive de type facial. Ann Endocrinol (Paris) 1999; 60: 157-66.
116. Orfanos CE, Zouboulis CC, Almond- Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53: 358-88.
117. Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, Viallette C, Revuz J. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: aretrospective study based on patients outcome assessment. Dermatology 2009; 218: 134-5.
118. Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; 40: 73-6.
119. Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol 2011; 164: 170-5.
120. Scheman AJ. Nodulocystic acne and hidradenitis suppurativa treated with acitretin: a case report. Cutis 2002; 69: 287-8.
121. Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol 1998; 19: 355-6.
122. Chow ET, Mortimer PS. Successful treatment of hidradenitis suppurativa and retroauricular acne with etretinate. Br J Dermatol 1992; 126: 415.
123. Grønhøj Larsen F, Steinkjer B, Jakobsen P, Hjorter A, Brockhoff PB, Nielsen-Kudsk F. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000; 143: 1164-9.
124. Gollnick HP, Dummler U. Retinoids. Clin Dermatol 1997; 15: 799-810.
125. Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case series of five patients. J Dermatolog Treat 2006; 17: 211-3.
126. Hofer T, Itin PH. Acne inversa: eine Dapson-sensitive Dermatose. Hautarzt 2001; 52: 989-92.
127. Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GB. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology 2011; 222: 342-6.
128. van der Zee HH, Prens EP. The antiinflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology 2011; 223: 169-73.
129. Brocard A, Knol AC, Khammari A, Dréno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology 2007; 215: 325-7.
130. Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, Griffiths CE, Cooper KD, Voorhees JJ. Oral ciclosporine in the treatment of inflammatory and noninflammatory dermatoses: a clinical and immuno- histopathologic study. Arch Dermatol 1990; 126: 339-50.
131. Buckley DA, Rogers S. Cylcosporin - responsive hidradenitis suppurativa. J R Soc Med 1995; 88: 289-90.
132. Rose RF, Goodfield MJD, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporine. Clin Exp Dermatol 2000; 31: 154-5.
133. Goo B, Chung HJ, Chung WG, Chung KY. Intramuscular immunoglobulin for recalcitrant suppurative diseases of the skin: a retrospective review of 63 cases. Br J Dermatol 2007; 157: 563-8.
134. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89: 595-600.
135. Karampetsou MP, Liossis SN, Sfikakis PP. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010; 103: 917-28.
136. Shuja F, Chan CS, Rosen T. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review. Dermatol Clin 2010; 28: 511-24.
137. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-17.
138. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165: 391-8.
139. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, Bachelez H, Morel P, Lebbé C. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-8.
140. Fernández-Vozmediano JM, Armario- Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology 2007; 215: 41-4.
141. Pedraz PJ, Daudén E, Pérez-Gala S, Goiriz-Valdés R, Fernández-Pẽas P, García-Diez A. Hidrosadenitis supurativa. Respuesta al tratamiento con infliximab. Actas Dermosifiliogr 2007; 98: 325-31.
142. Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol 2007; 32: 204-5.
143. Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative? Br J Dermatol 2008; 158: 361-3.
144. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-4.
145. Lasocki A, Sinclair R, Foley P, Saunders H. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol 2010; 51: 186-90.
146. Delage M, Samimi M, Atlan M, Machet L, Lorette G, Maruani A. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers. Acta Derm Venereol 2011; 91: 169-71.
147. van Rappard DC, Mooij JE, Baeten DL, Mekkes JR. New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab. Br J Dermatol 2011; 165: 194-8.
148. van Rappard DC, Leenarts MF, Meijerink-van t Oost L, Mekkes JR. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat 2011. [Epub ahead of print].
149. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 154: 726-9.
150. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, Stavrianeas N, Giamarellou H. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567-72.
151. Sotiriou E, Apalla Z, Ioannides D. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol 2009; 89: 82-3.
152. Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, Shin DB, Leyden JJ, Vittorio C, Gelfand JM. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60: 565-73.
153. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010; 146: 501-4.
154. Strober BE, Kim C, Siu K. Efalizumab for the treatment of refractory hidradenitis suppurativa. J Am Acad Dermatol 2007; 57: 1090-1.
155. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis CC, Kaklamanis P, Yazici H. Anti- TNF therapy in the management of Behets disease: Review and basis for recommendations. Rheumatology (Oxford) 2007; 46: 736-41.
156. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Müller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B. S3-Leitlinie zur Therapie der Psoriasis vulgaris - Update 2011. J Dtsch Dermatol Ges 2011; 9(Suppl 2): S1-104.
157. Yamauchi PS, Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol 2009; 8: 181-3.
158. Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández- Llaca H, Agudo M, González- López MA. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009; 145: 580-4.
159. Sotiriou E, Apalla Z, Vakirlis E, Ioannides D. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol 2009; 19: 180-1.
160. Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol 2010; 49: 950-5.
161. Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.Int J Dermatol 2010; 49: 1445-9.
162. Augustsson J, Eksborg S, Ernestam S, Gullstrom E, van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1462-6.
163. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008; 159: 527-36.
164. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
165. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 2004; 15: 280-94.
166. Diel R, Hauer B, Loddenkemper R, Manger B, Krüger K. Empfehlungen für das Tuberkulose-Screening vor Gabe von TNF-a-Inhibitoren bei rheumatischen Erkrankungen. Z Rheumatol 2009; 68: 411-6.
167. Zouboulis CC, Adams DA, Gu Y, Goldblum OM. Impact of weight and body mass index on high-sensitivity C-reactive protein response to adalimumab in hidradenitis suppurativa patients. J Am Acad Dermatol 2012; 66 (suppl 1): AB53.
168. OReilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg 2005; 116: 1575-6.
169. Sharon-Guidetti A, Ziv Y, Kummer E et al. Granulocyte macrophage colony- stimulating factor for perianal hidradenitis suppurativa: report of a case. Dis Colon Rectum 2006; 49: 682-4.
170. Bong JL, Shalders K, Saihan E. Treatment of persistent painful nodules of hidradenitis suppurativa with cryotherapy. Clin Exp Dermatol 2003; 28: 241-4.
171. Strauss RM, Pollock B, Stables GI, Goulden V, Cunliffe WJ. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol 2005; 152: 803-4.
172. Gold M, Bridges TM, Bradshaw VL, Boring M. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol 2004; 3(Suppl. 1): S32-5.
173. Rose RF, Stables GI. Topical photodynamic therapy in the treatment of hidradenitis suppurativa. Photodiagnosis Photodyn Ther 2008; 5: 171-5.
174. Sotiriou E, Apalla Z, Maliamani F, Ioannides D. Treatment of recalcitrant hidradenitis suppurativa with photodynamic therapy: report of five cases. Clin Exp Dermatol 2009; 34: e235-6.
175. Passeron T, Khemis A, Ortonne JP. Pulsed dye laser-mediated photodynamic therapy for acne inversa is not successful: a pilot study on four cases. J Dermatolog Treat 2009; 20: 297-8.
176. Goldschmidt H. Röntgentherapie von Dermatosen, Hidradenitis suppurativa. Handbuch der Haut und Geschlechtskrankheiten. Ergänzungsband V/2. Springer, Berlin, Heidelberg, New York, 1959: 541-4.
177. Frohlich D, Baaske D, Glatzel M. Radiotherapy of hidradenitis suppurativa - still valid today? Strahlenther Onkol 2000; 176: 286-9.
178. Seegenschmiedt MH, Katalinic A, Makoski HB, Haase W, Gademann G, Hassenstein E. Radiotherapy for benign diseases: patterns of case study in Germany. Int J Radiol Oncol Biol Phys 2000; 47: 195-202.